Find Alprostadil manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

USP

FDF DossiersDRUG PRODUCT COMPOSITIONS

17RELATED EXCIPIENT COMPANIES

24EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Prostaglandin e1, 745-65-3, Pge1, Edex, Caverject, Muse
Molecular Formula
C20H34O5
Molecular Weight
354.5  g/mol
InChI Key
GMVPRGQOIOIIMI-DWKJAMRDSA-N
FDA UNII
F5TD010360

Alprostadil
A potent vasodilator agent that increases peripheral blood flow.
Alprostadil is a Prostaglandin Analog and Prostaglandin E1 Agonist. The mechanism of action of alprostadil is as a Prostaglandin Receptor Agonist. The physiologic effect of alprostadil is by means of Genitourinary Arterial Vasodilation and Venous Vasodilation.
1 2D Structure

Alprostadil

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
2.1.2 InChI
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
2.1.3 InChI Key
GMVPRGQOIOIIMI-DWKJAMRDSA-N
2.1.4 Canonical SMILES
CCCCCC(C=CC1C(CC(=O)C1CCCCCCC(=O)O)O)O
2.1.5 Isomeric SMILES
CCCCC[C@@H](/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)O)O)O
2.2 Other Identifiers
2.2.1 UNII
F5TD010360
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Caverject

2. Edex

3. Lipo Pge1

4. Lipo-pge1

5. Minprog

6. Muse

7. Pge1

8. Pge1alpha

9. Prostaglandin E1

10. Prostaglandin E1alpha

11. Prostavasin

12. Prostin Vr

13. Prostine Vr

14. Sugiran

15. Vasaprostan

16. Viridal

2.3.2 Depositor-Supplied Synonyms

1. Prostaglandin E1

2. 745-65-3

3. Pge1

4. Edex

5. Caverject

6. Muse

7. Prostin Vr

8. Befar

9. Alprostadilum

10. Topiglan

11. Femprox

12. Alprox-td

13. L-prostaglandin E1

14. Liprostin

15. Prostandin

16. Vitaros

17. Prostin Vr Pediatric

18. Prink

19. Pge-1

20. Prostavasin

21. (11alpha,13e,15s)-11,15-dihydroxy-9-oxoprost-13-en-1-oic Acid

22. 7-((1r,2r,3r)-3-hydroxy-2-((s,e)-3-hydroxyoct-1-en-1-yl)-5-oxocyclopentyl)heptanoic Acid

23. Alprostadil(caverject)

24. (-)-prostaglandin E1

25. (13e)-(15s)-11alpha,15-dihydroxy-9-oxoprost-13-enoate

26. 11alpha,15alpha-dihydroxy-9-oxo-13-trans-prostenoic Acid

27. Chembl495

28. U-10136

29. 7-[(1r,2r,3r)-3-hydroxy-2-[(e,3s)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic Acid

30. Vasaprostan

31. Chebi:15544

32. 9-oxo-11r,15s-dihydroxy-13e-prostaenoic Acid

33. Ono-1608

34. U-10,136

35. F5td010360

36. Nsc-165559

37. Minprog

38. Sugiran

39. Viridal

40. (13e,15s)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic Acid

41. (1r,2r,3r)-3-hydroxy-2-((e)-(3s)-3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic Acid

42. Lipoprost

43. Promostan

44. Prostivas

45. Alista

46. Femlife

47. Prostaglandine1

48. Rayva

49. Caverject Impulse

50. Pge1alpha

51. 7-((1r,2r,3r)-3-hydroxy-2-((s,e)-3-hydroxyoct-1-enyl)-5-oxocyclopentyl)heptanoic Acid

52. 7-[(1r,3r)-3-hydroxy-2-[(1e,3s)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoic Acid

53. Smr000112594

54. Befar (tn)

55. Prink (tn)

56. Edex (tn)

57. Muse (tn)

58. (-)-protaglandin E1

59. U 10136

60. L-pge1

61. Sr-01000597593

62. Mr-256

63. Alprostadilum [inn-latin]

64. Prostin Vr Pediatric (tn)

65. Alprostadil Prostoglandin E1

66. Bml1-f06

67. Unii-f5td010360

68. Alprostadil(usan)

69. Hei-507

70. Ncgc00016535-01

71. Cas-745-65-3

72. Ono 1608

73. Einecs 212-017-2

74. (13e)-(15s)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate

75. Mfcd00077860

76. Nsc 165559

77. Alprostadil [usan:usp:inn:ban:jan]

78. 11,15-dihydroxy-9-oxoprost-13-en-1-oic Acid

79. Pge1;prostaglandin E1

80. Ai3-62116

81. Prestwick2_001018

82. Prestwick3_001018

83. Alprostadil [inn]

84. Alprostadil [jan]

85. Dsstox_cid_2578

86. Alprostadil [usan]

87. Alprostadil [vandf]

88. Pge1 (prostaglandin E1)

89. Alprostadil [mart.]

90. Dsstox_rid_76640

91. Dsstox_gsid_22578

92. Schembl33317

93. Alprostadil [usp-rs]

94. Alprostadil [who-dd]

95. Bspbio_001175

96. Bspbio_001488

97. Mls000758964

98. Mls001424250

99. Bidd:gt0747

100. Prostaglandin E1 [mi]

101. Bpbio1_001293

102. Gtpl1882

103. Alprostadil (jp17/usp/inn)

104. Dtxsid9022578

105. Alprostadil [orange Book]

106. Pge1, Prostaglandin E1, Powder

107. Alprostadil [usp Impurity]

108. Hms1361k10

109. Hms1571k17

110. Hms1791k10

111. Hms1989k10

112. Hms2052l11

113. Hms2090l08

114. Hms2098k17

115. Hms3268i09

116. Hms3402k10

117. Hms3414n09

118. Hms3648o17

119. Hms3678n07

120. Hms3715k17

121. Alprostadil [usp Monograph]

122. Amy30076

123. Bcp01740

124. Ex-a1411

125. Hy-b0131

126. Zinc3813088

127. Tox21_110482

128. 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic Acid

129. 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic Acid

130. Bdbm50101853

131. L-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentaneheptanoic Acid

132. Lmfa03010134

133. S1508

134. Akos015961103

135. Prost-13-en-1-oic Acid, 11,15-dihydroxy-9-oxo-, (11.alpha.,13e,15s)-

136. Prost-13-en-1-oic Acid, 11,15-dihydroxy-9-oxo-, (11alpha,13e,15s)-

137. Ac-6095

138. Bcp9000277

139. Ccg-101188

140. Cs-1905

141. Db00770

142. Nc00438

143. Idi1_033958

144. Prostaglandin E1, >=99.0% (tlc)

145. Smp2_000271

146. Ncgc00025234-02

147. Ncgc00025234-03

148. Ncgc00025234-04

149. Ncgc00025234-05

150. As-16360

151. Prostaglandin E1, Pge1, 745-65-3

152. Alprostadil 100 Microg/ml In Acetonitrile

153. 11,15-dihydroxy-9-oxoprost-13-en-1-oate

154. Ab00514004

155. B2154

156. P1917

157. Alprostadil, Meets Usp Testing Specifications

158. C04741

159. C76381

160. D00180

161. Prostaglandin E1, >=98% (hplc), Synthetic

162. Ab00514004-06

163. Ab00514004-08

164. Ab00514004_09

165. 11,15-dihydroxy-9-oxoprost-13-en-1-oic Acidl

166. 745p653

167. A838163

168. Q579348

169. Sr-01000946253

170. Sr-01000597593-1

171. Sr-01000597593-5

172. Sr-01000597593-6

173. Sr-01000946253-1

174. W-104416

175. Brd-k52459643-001-06-0

176. Brd-k52459643-001-10-2

177. Brd-k52459643-001-17-7

178. (13e)-(15s)-11,15-dihydroxy-9-oxoprost-13-enoate

179. (13e)-(15s)-11,15-dihydroxy-9-oxoprost-13-enoic Acid

180. Alprostadil, European Pharmacopoeia (ep) Reference Standard

181. (13e)-(15s)-11alpha,15-dihydroxy-9-oxoprost-13-enoic Acid

182. (11?,13e,15s)-11,15-dihydroxy-9-oxo-prost-13-en-1-oic Acid

183. (13e)-(15s)-11-alpha,15-dihydroxy-9-oxoprost-13-enoic Acid

184. 11,15-dihydroxy-9-oxoprost-13-en-1-oic Acid (acd/name 4.0)

185. 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate

186. Alprostadil, United States Pharmacopeia (usp) Reference Standard

187. (+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate

188. (+)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic Acid

189. (-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoate

190. (-)-3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-cyclopentaneheptanoic Acid

191. (11alpha,12alpha,13e,15s)-11,15-dihydroxy-9-oxoprost-13-en-1-oic Acid

192. Cyclopentaneheptanoic Acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, L-

193. Prost-13-en-1-oic Acid, 11,15-dihydroxy-9-oxo-, (11a,13e,15s)-

194. Prostaglandin E1, Synthetic, Powder, Bioreagent, Suitable For Cell Culture

195. Cyclopentaneheptanoic Acid, 3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxo-, (-)-

196. Prostaglandin E1, Powder, Gamma-irradiated, Bioxtra, Suitable For Cell Culture

197. Xpg

2.4 Create Date
2004-09-16
3 Chemical and Physical Properties
Molecular Weight 354.5 g/mol
Molecular Formula C20H34O5
XLogP33.2
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count13
Exact Mass354.24062418 g/mol
Monoisotopic Mass354.24062418 g/mol
Topological Polar Surface Area94.8 Ų
Heavy Atom Count25
Formal Charge0
Complexity432
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 12  
Drug NameCaverject
PubMed HealthAlprostadil
Drug ClassesEndocrine-Metabolic Agent, Erectile Dysfunction Agent, Prostaglandin
Drug LabelCAVERJECT contains alprostadil as the naturally occurring form of prostaglandin E1 (PGE1) and is designated chemically as (11,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid. The molecular weight is 354.49.Alprostadil is a white to off-white c...
Active IngredientAlprostadil
Dosage FormInjectable
RouteInjection
Strength0.005mg/vial; 0.02mg/vial; 0.04mg/vial; 0.01mg/vial
Market StatusPrescription
CompanyPharmacia And Upjohn

2 of 12  
Drug NameCaverject impulse
Drug LabelCAVERJECT contains alprostadil as the naturally occurring form of prostaglandin E1 (PGE1) and is designated chemically as (11,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid. The molecular weight is 354.49.Alprostadil is a white to off-white c...
Active IngredientAlprostadil
Dosage FormInjectable
RouteInjection
Strength0.02mg/vial; 0.01mg/vial
Market StatusPrescription
CompanyPharmacia And Upjohn

3 of 12  
Drug NameEdex
PubMed HealthAlprostadil
Drug ClassesEndocrine-Metabolic Agent, Erectile Dysfunction Agent, Prostaglandin
Drug Labeledex (alprostadil for injection) is a sterile, pyrogen-free powder containing alprostadil in an alfadex (-cyclodextrin) inclusion complex. Alprostadil is an endogenous substance known as prostaglandin E1 (PGE1). edex is supplied in single-dose,...
Active IngredientAlprostadil
Dosage FormInjectable
RouteInjection
Strength0.02mg/vial; 0.04mg/vial; 0.01mg/vial
Market StatusPrescription
CompanyAuxilium Pharms

4 of 12  
Drug NameMuse
PubMed HealthAlprostadil
Drug ClassesEndocrine-Metabolic Agent, Erectile Dysfunction Agent, Prostaglandin
Drug LabelMUSE (alprostadil) is a single-use, medicated transurethral system for the delivery of alprostadil to the male urethra. Alprostadil is suspended in polyethylene glycol 1450 (as excipient) and is formed into a medicated pellet (micro-suppository mea...
Active IngredientAlprostadil
Dosage FormSuppository
RouteUrethral
Strength0.5mg; 1mg; 0.25mg; 0.125mg
Market StatusPrescription
CompanyMeda Pharms

5 of 12  
Drug NameProstin vr pediatric
PubMed HealthAlprostadil
Drug ClassesEndocrine-Metabolic Agent, Erectile Dysfunction Agent, Prostaglandin
Drug LabelPROSTIN VR PEDIATRIC Sterile Solution for intravascular infusion contains 500 micrograms alprostadil, more commonly known as prostaglandin E1, in 1.0 mL dehydrated alcohol.The chemical name for alprostadil is (11,13E,15S)-11,15 dihydroxy-9-oxo-pros...
Active IngredientAlprostadil
Dosage FormInjectable
RouteInjection
Strength0.5mg/ml
Market StatusPrescription
CompanyPharmacia And Upjohn

6 of 12  
Drug NameAlprostadil
PubMed HealthAlprostadil
Drug ClassesEndocrine-Metabolic Agent, Erectile Dysfunction Agent, Prostaglandin
Drug LabelAlprostadil injection, USP for intravascular infusion contains 500 micrograms alprostadil, more commonly known as prostaglandin E1, in 1 mL dehydrated alcohol. The chemical name for alprostadil is (1R,2R,3R)3-Hydroxy-2-[(E)-(3S)-3-hydroxy-1-octenyl]-...
Active IngredientAlprostadil
Dosage FormInjectable
RouteInjection
Strength0.5mg/ml
Market StatusPrescription
CompanyTeva Pharms Usa; Eurohlth Intl

7 of 12  
Drug NameCaverject
PubMed HealthAlprostadil
Drug ClassesEndocrine-Metabolic Agent, Erectile Dysfunction Agent, Prostaglandin
Drug LabelCAVERJECT contains alprostadil as the naturally occurring form of prostaglandin E1 (PGE1) and is designated chemically as (11,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid. The molecular weight is 354.49.Alprostadil is a white to off-white c...
Active IngredientAlprostadil
Dosage FormInjectable
RouteInjection
Strength0.005mg/vial; 0.02mg/vial; 0.04mg/vial; 0.01mg/vial
Market StatusPrescription
CompanyPharmacia And Upjohn

8 of 12  
Drug NameCaverject impulse
Drug LabelCAVERJECT contains alprostadil as the naturally occurring form of prostaglandin E1 (PGE1) and is designated chemically as (11,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid. The molecular weight is 354.49.Alprostadil is a white to off-white c...
Active IngredientAlprostadil
Dosage FormInjectable
RouteInjection
Strength0.02mg/vial; 0.01mg/vial
Market StatusPrescription
CompanyPharmacia And Upjohn

9 of 12  
Drug NameEdex
PubMed HealthAlprostadil
Drug ClassesEndocrine-Metabolic Agent, Erectile Dysfunction Agent, Prostaglandin
Drug Labeledex (alprostadil for injection) is a sterile, pyrogen-free powder containing alprostadil in an alfadex (-cyclodextrin) inclusion complex. Alprostadil is an endogenous substance known as prostaglandin E1 (PGE1). edex is supplied in single-dose,...
Active IngredientAlprostadil
Dosage FormInjectable
RouteInjection
Strength0.02mg/vial; 0.04mg/vial; 0.01mg/vial
Market StatusPrescription
CompanyAuxilium Pharms

10 of 12  
Drug NameMuse
PubMed HealthAlprostadil
Drug ClassesEndocrine-Metabolic Agent, Erectile Dysfunction Agent, Prostaglandin
Drug LabelMUSE (alprostadil) is a single-use, medicated transurethral system for the delivery of alprostadil to the male urethra. Alprostadil is suspended in polyethylene glycol 1450 (as excipient) and is formed into a medicated pellet (micro-suppository mea...
Active IngredientAlprostadil
Dosage FormSuppository
RouteUrethral
Strength0.5mg; 1mg; 0.25mg; 0.125mg
Market StatusPrescription
CompanyMeda Pharms

11 of 12  
Drug NameProstin vr pediatric
PubMed HealthAlprostadil
Drug ClassesEndocrine-Metabolic Agent, Erectile Dysfunction Agent, Prostaglandin
Drug LabelPROSTIN VR PEDIATRIC Sterile Solution for intravascular infusion contains 500 micrograms alprostadil, more commonly known as prostaglandin E1, in 1.0 mL dehydrated alcohol.The chemical name for alprostadil is (11,13E,15S)-11,15 dihydroxy-9-oxo-pros...
Active IngredientAlprostadil
Dosage FormInjectable
RouteInjection
Strength0.5mg/ml
Market StatusPrescription
CompanyPharmacia And Upjohn

12 of 12  
Drug NameAlprostadil
PubMed HealthAlprostadil
Drug ClassesEndocrine-Metabolic Agent, Erectile Dysfunction Agent, Prostaglandin
Drug LabelAlprostadil injection, USP for intravascular infusion contains 500 micrograms alprostadil, more commonly known as prostaglandin E1, in 1 mL dehydrated alcohol. The chemical name for alprostadil is (1R,2R,3R)3-Hydroxy-2-[(E)-(3S)-3-hydroxy-1-octenyl]-...
Active IngredientAlprostadil
Dosage FormInjectable
RouteInjection
Strength0.5mg/ml
Market StatusPrescription
CompanyTeva Pharms Usa; Eurohlth Intl

4.2 Drug Indication

For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Alprostadil (prostaglandin E1) is produced endogenously to relax vascular smooth muscle and cause vasodilation. In adult males, the vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arteriolar inflow and expansion of the lacunar spaces within the corpora. As the expanded corporal sinusoids are compressed against the tunica albuginea, venous outflow through the subtunical vessels is impeded and penile rigidity develops. This is referred to as the corporal veno-occlusive mechanism. In infants, the vasodilatory effects of alprostadil increase pulmonary or systemic blood flow.


5.2 MeSH Pharmacological Classification

Vasodilator Agents

Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)


Urological Agents

Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)


Platelet Aggregation Inhibitors

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
ALPROSTADIL
5.3.2 FDA UNII
F5TD010360
5.3.3 Pharmacological Classes
Prostaglandin Analog [EPC]; Prostaglandin E1 Agonist [EPC]; Prostaglandin Receptor Agonists [MoA]; Prostaglandins [CS]; Venous Vasodilation [PE]; Genitourinary Arterial Vasodilation [PE]
5.4 ATC Code

C - Cardiovascular system

C01 - Cardiac therapy

C01E - Other cardiac preparations

C01EA - Prostaglandins

C01EA01 - Alprostadil


G - Genito urinary system and sex hormones

G04 - Urologicals

G04B - Urologicals

G04BE - Drugs used in erectile dysfunction

G04BE01 - Alprostadil


5.5 Absorption, Distribution and Excretion

Absorption

The absolute bioavailability of alprostadil has not been determined.


Route of Elimination

Alprostadil must be infused continuously because it is very rapidly metabolized. As much as 80% of the circulating alprostadil may be metabolized in one pass through the lungs, primarily by - and -oxidation. The metabolites are excreted primarily by the kidney, and excretion is essentially complete within 24 hours after administration.


5.6 Metabolism/Metabolites

Alprostadil must be infused continuously because it is very rapidly metabolized. As much as 80% of the circulating alprostadil may be metabolized in one pass through the lungs, primarily by beta- and omega-oxidation.


5.7 Biological Half-Life

5 to 10 minutes (after a single dose), in healthy adults and neonates.


5.8 Mechanism of Action

Alprostadil causes vasodilation by means of a direct effect on vascular and ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This is because, as a form of prostaglandinE1 (PGE1) it has multiple effects on blood flow. This results in increased pulmonary or systemic blood flow in infants. In cyanotic congenital heart disease, alprostadil's actions result in an increased oxygen supply to the tissues. In infants with interrupted aortic arch or very severe aortic coarctation, alprostadil maintains distal aortic perfusion by permitting blood flow through the DA from the pulmonary artery to the aorta. In infants with aortic coarctation, alprostadil reduces aortic obstruction either by relaxing ductus tissue in the aortic wall or by increasing effective aortic diameter by dilating the DA. In infants with these aortic arch anomalies, systemic blood flow to the lower body is increased, improving tissue oxygen supply and renal perfusion. When administered by intracavernosal injection or as an intraurethral suppository, alprostadil acts locally to relax the trabecular smooth muscle of the corpora cavernosa and the cavernosal arteries. Swelling, elongation, and rigidity of the penis result when arterial blood rapidly flows into the corpus cavernosum to expand the lacunar spaces. The entrapped blood reduces the venous blood outflow as sinusoids compress against the tunica albuginea.


API SUPPLIERS

read-more
read-more

01

Chirogate International

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChirogate is a professional Prostaglandin manufacturer.

Flag Taiwan
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Chirogate CB

02

EUROAPI

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Flag France
Digital Content Digital Content
USDMF arrow-down CEP/COS arrow-down JDMF arrow-down EU-WC NDC arrow-down KDMF arrow-down VMF CN arrow-down AUDIT arrow-down
EUROAPI Compnay Banner

03

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB

04

TIEN (Tianjin) Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

TIEN (Tianjin) Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

05

Everlight Chemical

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Everlight Chemical

Taiwan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

06

Ono Pharmaceutical

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Ono Pharmaceutical

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
blank

07

Ono Pharmaceutical

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Ono Pharmaceutical

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Evotec

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Evotec

Germany

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Nissan Chemical

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Nissan Chemical

Japan

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

CASCADE BIOCHEMICAL LTD

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

CASCADE BIOCHEMICAL LTD

United Kingdom

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Flag France
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 10948

Submission : 1994-06-20

Status : Active

Type : II

EUROAPI Compnay Banner

02

Cascade Biochemical Ltd

United Kingdom

USDMF

arrow
PEGS Boston Summit
Not Confirmed

02

Cascade Biochemical Ltd

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 12569

Submission : 1997-07-02

Status : Inactive

Type : II

blank

03

PEGS Boston Summit
Not Confirmed

03

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2016-04-06

Pay. Date : 2015-07-16

DMF Number : 21233

Submission : 2008-01-15

Status : Active

Type : II

blank

04

Evotec Oai

Germany

USDMF

arrow
PEGS Boston Summit
Not Confirmed

04

Evotec Oai

Germany
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 13249

Submission : 1998-09-30

Status : Inactive

Type : II

blank

05

PEGS Boston Summit
Not Confirmed

05

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 11845

Submission : 1996-02-06

Status : Inactive

Type : II

blank

06

PEGS Boston Summit
Not Confirmed

06

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 21906

Submission : 2008-07-30

Status : Inactive

Type : II

blank

07

PEGS Boston Summit
Not Confirmed

07

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 11534

Submission : 1995-05-31

Status : Inactive

Type : II

blank

08

PEGS Boston Summit
Not Confirmed

08

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 34239

Submission : 2020-04-21

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

read-more
read-moreread-more
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Flag France
Digital Content Digital Content
R1-CEP 2015-302 - Rev 00
Valid
Chemical
2022-01-31
1488
EUROAPI Compnay Banner

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Flag France
Digital Content Digital Content

Certificate Number : R1-CEP 2015-302 - Rev 00

Status : Valid

Issue Date : 2022-01-31

Type : Chemical

Substance Number : 1488

EUROAPI Compnay Banner

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Certificate Number : CEP 2012-204 - Rev 02

Status : Valid

Issue Date : 2025-10-28

Type : Chemical

Substance Number : 1488

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more
  • Development Update

Details:

Eubeatline (alprostadil), is a Prostaglandin E1 agonist, which is being evaluated for the treatment of severe heart failure in adults.


Lead Product(s): Alprostadil,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Eubeatline

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Medical Center of Vienna

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 18, 2023

blank

01

Biopeutics

Country
arrow
PEGS Boston Summit
Not Confirmed

Biopeutics

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Eubeatline (alprostadil), is a Prostaglandin E1 agonist, which is being evaluated for the treatment of severe heart failure in adults.

Product Name : Eubeatline

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 18, 2023

blank
  • Development Update

Details:

Alprostadil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acute Kidney Injury.


Lead Product(s): Alprostadil,Inapplicable

Therapeutic Area: Nephrology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 27, 2022

blank

02

CSPC ZhongQi

Country
arrow
PEGS Boston Summit
Not Confirmed

CSPC ZhongQi

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Alprostadil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acute Kidney Injury.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 27, 2022

blank

Details:

Advanz get the rights to a portfolio of alprostadil products including, Prostavasin, Viridal, Vasaprostan and Edex, which consists of injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease, in 20 countries.


Lead Product(s): Alprostadil,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Prostavasin

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Advanz Pharma

Deal Size: $96.0 million Upfront Cash: $96.0 million

Deal Type: Acquisition April 01, 2020

blank

03

UCB Pharma S.A

Belgium
arrow
PEGS Boston Summit
Not Confirmed

UCB Pharma S.A

Belgium
arrow
PEGS Boston Summit
Not Confirmed

Details : Advanz get the rights to a portfolio of alprostadil products including, Prostavasin, Viridal, Vasaprostan and Edex, which consists of injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive dis...

Product Name : Prostavasin

Product Type : Miscellaneous

Upfront Cash : $96.0 million

April 01, 2020

blank

Details:

The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.


Lead Product(s): Alprostadil,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Prostavasin

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Advanz Pharma

Deal Size: $98.0 million Upfront Cash: $84.0 million

Deal Type: Agreement March 06, 2020

blank

04

UCB Pharma S.A

Belgium
arrow
PEGS Boston Summit
Not Confirmed

UCB Pharma S.A

Belgium
arrow
PEGS Boston Summit
Not Confirmed

Details : The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.

Product Name : Prostavasin

Product Type : Miscellaneous

Upfront Cash : $84.0 million

March 06, 2020

blank
  • Development Update

Details:

Alprostadil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arterial Occlusive Diseases.


Lead Product(s): Alprostadil,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 13, 2018

blank

05

CSPC ZhongQi

Country
arrow
PEGS Boston Summit
Not Confirmed

CSPC ZhongQi

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Alprostadil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arterial Occlusive Diseases.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 13, 2018

blank
  • Development Update

Details:

IHIVARNA-01 is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.


Lead Product(s): iHIVARNA-01,Alprostadil,Papaverine Hydrochloride,Phentolamine Mesylate

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Vaccine

Sponsor: Institut d'Investigacions Biomèdiques | IrsiCaixa | Institute of Tropical Medicine, Belgium | Vrije Universiteit Brussel | Synapse bv | Asphalion | eTheRNA immunotherapies | CR2O | Hospital Clinic of Barcelona | Germans Trias i Pujol Hospital | Universita

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 05, 2016

blank

06

Institut d'Investigacions Biom?diques

Country
arrow
PEGS Boston Summit
Not Confirmed

Institut d'Investigacions Biom?diques

Country
arrow
PEGS Boston Summit
Not Confirmed

Lead Product(s) : iHIVARNA-01,Alprostadil,Papaverine Hydrochloride,Phentolamine Mesylate

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : Institut d'Investigacions Biomèdiques | IrsiCaixa | Institute of Tropical Medicine, Belgium | Vrije Universiteit Brussel | Synapse bv | Asphalion | eTheRNA immunotherapies | CR2O | Hospital Clinic of Barcelona | Germans Trias i Pujol Hospital | Universita

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : IHIVARNA-01 is a Vaccine drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.

Product Name : Undisclosed

Product Type : Vaccine

Upfront Cash : Inapplicable

September 05, 2016

blank

Details:

Alprostadil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Raynaud Disease.


Lead Product(s): Alprostadil,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 29, 2014

blank

07

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Alprostadil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Raynaud Disease.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 29, 2014

blank

Details:

WC3036-12F is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Erectile Dysfunction.


Lead Product(s): WC3036-12F,Alprostadil

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Undisclosed

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 13, 2013

blank

08

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : WC3036-12F is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Erectile Dysfunction.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Inapplicable

March 13, 2013

blank

Details:

Tracleer is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Raynaud Disease.


Lead Product(s): Bosentan Hydrate,Alprostadil

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Miscellaneous

Sponsor: Christoph Hehrlein

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 22, 2011

blank

09

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Tracleer is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Raynaud Disease.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 22, 2011

blank

Details:

Alprostadil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arterial Occlusive Diseases.


Lead Product(s): Alprostadil,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 21, 2010

blank

10

UCB Pharma S.A

Belgium
arrow
PEGS Boston Summit
Not Confirmed

UCB Pharma S.A

Belgium
arrow
PEGS Boston Summit
Not Confirmed

Details : Alprostadil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arterial Occlusive Diseases.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 21, 2010

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Ethypharm

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEthypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Flag France
Digital Content Digital Content

Regulatory Info :

Registration Country : France

Alprostadil

Brand Name :

Dosage Form : Powder for Solution for Infusion

Dosage Strength : 20MCG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : France

Ethypharm

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : EDEX

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.005MG/VIAL

Packaging :

Approval Date : 1997-06-12

Application Number : 20649

Regulatory Info : DISCN

Registration Country : USA

blank

03

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : EDEX

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.01MG/VIAL

Packaging :

Approval Date : 1997-06-12

Application Number : 20649

Regulatory Info : RX

Registration Country : USA

blank

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : EDEX

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.02MG/VIAL

Packaging :

Approval Date : 1997-06-12

Application Number : 20649

Regulatory Info : RX

Registration Country : USA

blank

05

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : EDEX

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.04MG/VIAL

Packaging :

Approval Date : 1997-06-12

Application Number : 20649

Regulatory Info : RX

Registration Country : USA

blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : EDEX

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.01MG/VIAL

Packaging :

Approval Date : 1998-07-30

Application Number : 20649

Regulatory Info : RX

Registration Country : USA

blank

07

Pfizer Inc

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : PROSTIN VR PEDIATRIC

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.5MG/ML

Packaging :

Approval Date : 1982-01-01

Application Number : 18484

Regulatory Info : RX

Registration Country : USA

blank

08

Pfizer Inc

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : CAVERJECT

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.01MG/VIAL

Packaging :

Approval Date : 1995-07-06

Application Number : 20379

Regulatory Info : RX

Registration Country : USA

blank

09

Pfizer Inc

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : CAVERJECT

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.02MG/VIAL

Packaging :

Approval Date : 1995-07-06

Application Number : 20379

Regulatory Info : RX

Registration Country : USA

blank

10

Pfizer Inc

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Pfizer Inc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : CAVERJECT

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.005MG/VIAL

Packaging :

Approval Date : 1996-06-27

Application Number : 20379

Regulatory Info : DISCN

Registration Country : USA

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

ENDO OPERATIONS

Ireland
PEGS Boston Summit
Not Confirmed
arrow

ENDO OPERATIONS

Ireland
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : EDEX

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.005MG/VIAL

Approval Date : 1997-06-12

Application Number : 20649

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

02

MEITHEAL

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

MEITHEAL

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : ALPROSTADIL

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.5MG/ML

Approval Date : 1999-04-30

Application Number : 75196

RX/OTC/DISCN : RX

RLD : No

TE Code : AP

blank

03

PFIZER

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

PFIZER

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : CAVERJECT

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.01MG/VIAL

Approval Date : 1995-07-06

Application Number : 20379

RX/OTC/DISCN : RX

RLD : Yes

TE Code : AP

blank

04

PFIZER

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

PFIZER

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : CAVERJECT

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.02MG/VIAL

Approval Date : 1995-07-06

Application Number : 20379

RX/OTC/DISCN : RX

RLD : Yes

TE Code : AP

blank

05

PFIZER

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

PFIZER

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : CAVERJECT

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.005MG/VIAL

Approval Date : 1996-06-27

Application Number : 20379

RX/OTC/DISCN : DISCN

RLD : Yes

TE Code :

blank

06

PFIZER

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

PFIZER

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : CAVERJECT

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.04MG/VIAL

Approval Date : 1997-05-19

Application Number : 20379

RX/OTC/DISCN : RX

RLD : Yes

TE Code : AP

blank

07

PFIZER

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

PFIZER

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : CAVERJECT

Dosage Form : INJECTABLE;INJECTION

Dosage Strength : 0.005MG/ML

Approval Date : 1997-10-31

Application Number : 20755

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank

08

VIATRIS

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

VIATRIS

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : MUSE

Dosage Form : SUPPOSITORY;URETHRAL

Dosage Strength : 0.125MG

Approval Date : 1996-11-19

Application Number : 20700

RX/OTC/DISCN : DISCN

RLD : Yes

TE Code :

blank

09

VIATRIS

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

VIATRIS

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : MUSE

Dosage Form : SUPPOSITORY;URETHRAL

Dosage Strength : 0.25MG

Approval Date : 1996-11-19

Application Number : 20700

RX/OTC/DISCN : DISCN

RLD : Yes

TE Code :

blank

10

VIATRIS

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

VIATRIS

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

ALPROSTADIL

Brand Name : MUSE

Dosage Form : SUPPOSITORY;URETHRAL

Dosage Strength : 0.5MG

Approval Date : 1996-11-19

Application Number : 20700

RX/OTC/DISCN : DISCN

RLD : Yes

TE Code :

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

2Care4 Aps

Denmark
PEGS Boston Summit
Not Confirmed
arrow

2Care4 Aps

Denmark
arrow
PEGS Boston Summit
Not Confirmed

Alprostadil

Brand Name : Caverject Dual

Dosage Form : Powder And Solvents For Solution For Injection

Dosage Strength : 20mcg

Packaging :

Approval Date : 31-08-2022

Application Number : 28106795022

Regulatory Info : Prescription

Registration Country : Denmark

blank

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Alprostadil

Brand Name : Bondil

Dosage Form : Urethral Pin

Dosage Strength : 1000mcg

Packaging :

Approval Date : 21-09-2021

Application Number : 2.02E+13

Regulatory Info : Deregistered

Registration Country : Sweden

blank

03

Orifarm Ab

Denmark
PEGS Boston Summit
Not Confirmed
arrow

Orifarm Ab

Denmark
arrow
PEGS Boston Summit
Not Confirmed

Alprostadil

Brand Name : Bondil

Dosage Form : Urethral Pin

Dosage Strength : 500mcg

Packaging :

Approval Date : 24-05-2017

Application Number : 2.02E+13

Regulatory Info : Deregistered

Registration Country : Sweden

blank

04

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Alprostadil

Brand Name : Caverject

Dosage Form : Alprostadil 10Mcg 1 Units Use Intracavernoso

Dosage Strength : 1 vial 10 mcg + syringe + 2 needles

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

05

Pfizer Ag

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Pfizer Ag

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Alprostadil

Brand Name : Caverject DC

Dosage Form : Solution For Injection

Dosage Strength : 20mcg/5ml

Packaging :

Approval Date : 06/03/2002

Application Number : 55674

Regulatory Info : Allowed

Registration Country : Switzerland

blank

06

Pfizer Sl

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Pfizer Sl

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Alprostadil

Brand Name : Alprostadil Pfizer

Dosage Form : Injectable Solution

Dosage Strength : 0.5MG

Packaging :

Approval Date : 01-05-1983

Application Number : 56120

Regulatory Info : Authorized

Registration Country : Spain

blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Alprostadil

Brand Name : Alprostar

Dosage Form : Alprostadil 20Mcg 1 Unit Parenteral Use

Dosage Strength : 1 ampoule EV EA 20 mcg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

08

Viatris AS

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Viatris AS

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Alprostadil

Brand Name : Bondil

Dosage Form : Urethral Plug

Dosage Strength : 250mcg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Not Marketed

Registration Country : Norway

blank

09

Viatris AS

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Viatris AS

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Alprostadil

Brand Name : Bondil

Dosage Form : Urethral Plug

Dosage Strength : 500mcg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Not Marketed

Registration Country : Norway

blank

10

Viatris Sia

U.S.A
PEGS Boston Summit
Not Confirmed
arrow

Viatris Sia

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Alprostadil

Brand Name : Muse 500Mcg

Dosage Form : Urethral Stick

Dosage Strength : 500mcg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - INJECTABLE;INJECTION - 0.005MG/VIAL

USFDA APPLICATION NUMBER - 20379

read-more

DOSAGE - INJECTABLE;INJECTION - 0.01MG/VIAL

USFDA APPLICATION NUMBER - 20379

read-more

DOSAGE - INJECTABLE;INJECTION - 0.02MG/VIAL

USFDA APPLICATION NUMBER - 20379

read-more

DOSAGE - INJECTABLE;INJECTION - 0.04MG/VIAL

USFDA APPLICATION NUMBER - 20379

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Parenteral

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

Grade : Parenteral, Oral, Topical

Category : Parenteral, Solubilizers, Topical

02

Kirsch Pharma

Germany
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHigh-quality raw materials and custom blends for pharma, biopharma, nutrition, veterinary, and cosmetics worldwide.

Grade : Biopharma Grade

Category : Parenteral

Brand Name : Sodium Chloride

Excipient Details : Used as an osmolarity agent in culture media, tonicity adjuster in ophthalmics and parenterals solutions.

Pharmacopoeia Ref : On Request

Technical Specs : Low bacteria endotoxins, low bioburden (TAMC/TYMC). Customised pa...

arrow

03

Kirsch Pharma

Germany
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHigh-quality raw materials and custom blends for pharma, biopharma, nutrition, veterinary, and cosmetics worldwide.

Grade : Biopharma Grade

Category : Parenteral

Brand Name : Trisodium Citrate

Excipient Details : Used as a buffering agent in purification process during downstream and in the final formulation.

Pharmacopoeia Ref : On Request

Technical Specs : Low bacteria endotoxins, low bioburden (TAMC/TYMC). Customised pa...

arrow

04

Finar

India
PEGS Boston Summit
Not Confirmed
arrow

Topical

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

Grade : Parenteral, Oral, Topical

Category : Parenteral, Solubilizers, Topical

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDr. Paul Lohmann® provides premium mineral salts backed by 140+ years of innovation, quality manufacturing, and global expertise.

Grade : Oral

Category : API Stability Enhancers, Topical

04

Finar

India
PEGS Boston Summit
Not Confirmed
arrow

Solubilizers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

Grade : Parenteral, Oral, Topical

Category : Parenteral, Solubilizers, Topical

03

Finar

India
PEGS Boston Summit
Not Confirmed
arrow

Granulation

read-more
read-more

01

BASF

Germany
PEGS Boston Summit
Not Confirmed
arrow

Direct Compression

read-more
read-more

01

BASF

Germany
PEGS Boston Summit
Not Confirmed
arrow

Chewable & Orodispersible Aids

read-more
read-more

API Stability Enhancers

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Co-Processed Excipients

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Coating Systems & Additives

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

EDQM

read-more
read-more

01

EDQM, Council of Europe

Dinoprostone impurity C

arrow
PEGS Boston Summit
Not Confirmed

01

PEGS Boston Summit
Not Confirmed

Dinoprostone impurity C

CAS Number : n/a

Quantity Per Vial : 10 mg

Sale Unit : 1

Order Code : D2250015

Batch No : 2

Price (€) : 240

Storage : -20°C ± 5°C

blank

02

PEGS Boston Summit
Not Confirmed

02

PEGS Boston Summit
Not Confirmed

Alprostadil

CAS Number : 745-65-3

Quantity Per Vial : 25 mg

Sale Unit : 1

Order Code : Y0000054

Batch No : 3

Price (€) : 79

Storage : -20°C ± 5°C

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
read-more

01

PEGS Boston Summit
Not Confirmed

01

PEGS Boston Summit
Not Confirmed

Alprostadil

Monograph in Japanese Pharmacopoeia : Alprostadi...

Package Size : 10 mg

Price (¥) : 65,623

Storage Temperature °C : 5°C

Assay Test : I/ UV-VIS I/ IR

blank

02

PEGS Boston Summit
Not Confirmed

02

PEGS Boston Summit
Not Confirmed

Alprostadil

Monograph in Japanese Pharmacopoeia :

Package Size : 10 mg

Price (¥) : 65,623

Storage Temperature °C : 5°C

Assay Test : A/ LC

blank

03

PEGS Boston Summit
Not Confirmed

03

PEGS Boston Summit
Not Confirmed

Alprostadil

Monograph in Japanese Pharmacopoeia : Alprostadi...

Package Size : 10 mg

Price (¥) : 65,623

Storage Temperature °C : 5°C

Assay Test : I/ TLC A/ LC

blank

04

PEGS Boston Summit
Not Confirmed

04

PEGS Boston Summit
Not Confirmed

Alprostadil

Monograph in Japanese Pharmacopoeia : Alprostadi...

Package Size : 10 mg

Price (¥) : 65,623

Storage Temperature °C : 5°C

Assay Test : A/ LC

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Others

read-more
read-more

01

XYZ Pharma

Country
arrow
PEGS Boston Summit
Not Confirmed

XYZ Pharma

Country
arrow
PEGS Boston Summit
Not Confirmed

Alprostadil (25 mg)

CAS Number : 745-65-3

Quantity Per Vial : 25

Sale Unit : mg

Price : $2,375. 00

Details : Material Origin- Chemical Synthesis; USMCA- N...

Monograph :

Storage :

Code/Batch No : Catalog #1016000 / R061F0

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 745-65-3 / Alprostadil API manufacturers, exporters & distributors?

Alprostadil manufacturers, exporters & distributors 1

29

PharmaCompass offers a list of Alprostadil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Alprostadil manufacturer or Alprostadil supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Alprostadil manufacturer or Alprostadil supplier.

API | Excipient name

Alprostadil

Synonyms

Prostaglandin e1, 745-65-3, Pge1, Edex, Caverject, Muse

Cas Number

745-65-3

Unique Ingredient Identifier (UNII)

F5TD010360

About Alprostadil

A potent vasodilator agent that increases peripheral blood flow.

FemLife Manufacturers

A FemLife manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of FemLife, including repackagers and relabelers. The FDA regulates FemLife manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. FemLife API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of FemLife manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

FemLife Suppliers

A FemLife supplier is an individual or a company that provides FemLife active pharmaceutical ingredient (API) or FemLife finished formulations upon request. The FemLife suppliers may include FemLife API manufacturers, exporters, distributors and traders.

click here to find a list of FemLife suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

FemLife USDMF

A FemLife DMF (Drug Master File) is a document detailing the whole manufacturing process of FemLife active pharmaceutical ingredient (API) in detail. Different forms of FemLife DMFs exist exist since differing nations have different regulations, such as FemLife USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A FemLife DMF submitted to regulatory agencies in the US is known as a USDMF. FemLife USDMF includes data on FemLife's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The FemLife USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of FemLife suppliers with USDMF on PharmaCompass.

FemLife JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The FemLife Drug Master File in Japan (FemLife JDMF) empowers FemLife API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the FemLife JDMF during the approval evaluation for pharmaceutical products. At the time of FemLife JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of FemLife suppliers with JDMF on PharmaCompass.

FemLife KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a FemLife Drug Master File in Korea (FemLife KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of FemLife. The MFDS reviews the FemLife KDMF as part of the drug registration process and uses the information provided in the FemLife KDMF to evaluate the safety and efficacy of the drug.

After submitting a FemLife KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their FemLife API can apply through the Korea Drug Master File (KDMF).

click here to find a list of FemLife suppliers with KDMF on PharmaCompass.

FemLife CEP

A FemLife CEP of the European Pharmacopoeia monograph is often referred to as a FemLife Certificate of Suitability (COS). The purpose of a FemLife CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of FemLife EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of FemLife to their clients by showing that a FemLife CEP has been issued for it. The manufacturer submits a FemLife CEP (COS) as part of the market authorization procedure, and it takes on the role of a FemLife CEP holder for the record. Additionally, the data presented in the FemLife CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the FemLife DMF.

A FemLife CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. FemLife CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of FemLife suppliers with CEP (COS) on PharmaCompass.

FemLife NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing FemLife as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for FemLife API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture FemLife as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain FemLife and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a FemLife NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of FemLife suppliers with NDC on PharmaCompass.

FemLife GMP

FemLife Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of FemLife GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right FemLife GMP manufacturer or FemLife GMP API supplier for your needs.

FemLife CoA

A FemLife CoA (Certificate of Analysis) is a formal document that attests to FemLife's compliance with FemLife specifications and serves as a tool for batch-level quality control.

FemLife CoA mostly includes findings from lab analyses of a specific batch. For each FemLife CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

FemLife may be tested according to a variety of international standards, such as European Pharmacopoeia (FemLife EP), FemLife JP (Japanese Pharmacopeia) and the US Pharmacopoeia (FemLife USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty